Vaccine formulations that enhance Th1 levels and CD8+ T-cell responses are highly sought after as they are effective for immunization against pathogens for which there are no currently licensed vaccines (examples: HIV-AIDS, malaria, and tuberculosis) [66]. This evidence concerns the gene CD8A and tuberculosis.